Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61M AND EN_ALLTXT:(coronavirus OR coronaviruses OR coronaviridae OR coronavirinae OR orthocoronavirus OR orthocoronaviruses OR orthocoronaviridae OR orthocoronavirinae OR betacoronavirus OR betacoronaviruses OR betacoronaviridae OR betacoronavirinae OR sarbecovirus OR sarbecoviruses OR sarbecoviridae OR sarbecovirinae OR "severe acute respiratory syndrome" OR sars OR "2019 ncov" OR covid)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2021/181261LACTOFERRIN FOR ORAL INHALATION USE FOR THE TREATMENT OF A DISEASE CAUSED BY A SARS-CORONA VIRUS
WO 16.09.2021
Int.Class A61K 38/40
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
40Transferrins, e.g. lactoferrins, ovotransferrins
Appl.No PCT/IB2021/051941 Applicant SOFAR S.P.A. Inventor BIFFI, Andrea
The present invention relates to a composition comprising lactoferrin for inhalation use in the treatment of viral infections of the respiratory system, and related symptoms or disorders, caused by a SARS- coronavirus (e.g. COVID-19 disease). In addition, the present invention relates to a device for the administration - through the inhalation route - of said composition comprising lactoferrin and the use thereof in said methods for the treatment of viral infections.
2.WO/2021/243372CLOSED-LOOP ANTIMICROBIAL PHOTO-PLASMAPHERESIS
WO 02.12.2021
Int.Class A61M 1/36
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
1Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
36Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation
Appl.No PCT/US2021/070633 Applicant BAYLOR COLLEGE OF MEDICINE Inventor SZIGETI, Reka
The present disclosure concerns systems and methods related to the treatment, prevention, delay of onset, or reduction of severity of a microbial infection in an individual, including closed-loop plasmapheresis and extracorporeal light irradiation of the plasma of the individual. The systems and methods further relate to irradiation of the plasma of the individual with UV and/or visible light, optionally in the presence of a photosensitizer. The systems and methods further relate to light irradiation inactivation of microbial particles in the plasma taken from the individual. The systems and methods further relate to the optional filtration of microbial particles from UV light-treated plasma. The systems and methods further relate to reinfusion of the UV light-treated, optionally filtered, plasma back into the individual. The systems and methods further relate to treating, preventing, delaying onset of, or reducing in severity a viral infection, particularly a viral infection caused by a Coronaviridae family virus, at least including SARS-CoV-2. The systems and methods are further configured to reduce viral load and/or lymphocyte reinfection rate in the individual.
3.WO/2021/167862TREATMENT OF A VIRAL PANDEMIC USING CIGARETTES WITH ADDED NITRATES
WO 26.08.2021
Int.Class C01B 21/24
CCHEMISTRY; METALLURGY
01INORGANIC CHEMISTRY
BNON-METALLIC ELEMENTS; COMPOUNDS THEREOF
21Nitrogen; Compounds thereof
20Nitrogen oxides; Oxyacids of nitrogen; Salts thereof
24Nitric oxide (NO)
Appl.No PCT/US2021/018111 Applicant FINE, David H. Inventor FINE, David H.
A modified cigarette is used as a low-cost, widely available combustion engine to deliver high-dose nitric oxide (NO) directly into the lungs of people ill from a viral lung pandemic, similar to the influenza virus or the coronavirus.
4.20210252033N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTI-VIRAL USES RELATED THERETO
US 19.08.2021
Int.Class A61K 31/7068
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7042Compounds having saccharide radicals and heterocyclic rings
7052having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
706containing six-membered rings with nitrogen as a ring hetero atom
7064containing condensed or non-condensed pyrimidines
7068having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
Appl.No 17170172 Applicant Emory University Inventor George R. PAINTER

This disclosure relates to certain N4-hydroxycytidine derivatives, pharmaceutical compositions, and methods related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of human coronavirus 2019-nCoV.

5.20210338631SYSTEMS AND METHODS FOR TREATING CORONAVIRUS
US 04.11.2021
Int.Class A61K 31/353
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
35having six-membered rings with one oxygen as the only ring hetero atom
352condensed with carbocyclic rings, e.g. cannabinols, methantheline
3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
Appl.No 17222718 Applicant Michael Mong Inventor Michael Mong

Provided herein are methods of treatment, including methods of treating subjects having or at risk of having or having a viral infection, and specifically a SARS-CoV-2 viral infection. The methods provided include the administration of 4-methylumbelliferone (4-MU), palmitoylethanolamide (PEA), reservatrol, fisetin, H2, nebulized hyaluronidase or combinations thereof. Also provided herein are a respiratory assistance device, methods of generating a customized respiratory assistance device, methods of treating a coronavirus infection, and methods of inhibiting a coronavirus infectivity, virulence and/or spread.

6.WO/2021/224899INTEGRABLE MICROPROCESSOR CONTROLLED DELIVERY DEVICE FOR TREATING CORONAVIRUS INCLUDING COVID-19 AND METHOD THEREOF
WO 11.11.2021
Int.Class A61M 16/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
16Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
Appl.No PCT/IB2021/054538 Applicant KHAITAN, Mahesh Kumar Inventor KHAITAN, Mahesh Kumar
The present invention discloses a device for COVID-19 treatment by pH modulation involving alkalization of the respiratory tract using an integrable microprocessor controlled delivery device. The device consists of an Aerosolizer (3) which delivers specific agents in aerosol form; a microprocessor (4) which automatically controls delivery of the agents, without human intervention and a variable syringe (1) with pump or driver to deliver agents to the Aerosolizer. The device can be easily integrated with a humidifier (10) or a ventilator (11). Two agents are delivered in conjunction by the device. One agent is a physiologically compatible alkalizing agent viz. aqueous solution of sodium bicarbonate of strength 3 – 8.4%, pH ranging between 8 - 8.6 at 20°C, which leads to inactivation of the virus and prevents spread of the disease. Other agent is an anti-inflammatory corticosteroid ciclesonide delivered in quantity of 160-200 micrograms per day which prevents bronchospasms.
7.WO/2022/049420METHOD OF PLANT-BASED INHALATION FOR THE TREATMENT OF RESPIRATORY VIRUSES
WO 10.03.2022
Int.Class A61K 31/015
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
01Hydrocarbons
015carbocyclic
Appl.No PCT/IB2021/000596 Applicant WEBB, Yvette, Rose Inventor WEBB, Yvette, Rose
Pinene compositions are described that may be used to treat respiratory viruses and method of treating a respiratory virus by inhaling an atomized pinene composition. The pinenes composition may comprise an expedient and pinene. The pinene composition comprises pinene in a concentration of greater than 80% by weight of the pinene composition. The methods of treatment of the respiratory virus includes filling a reservoir bottle of an atomizer with a liquid substance, the liquid substance being comprised of pinene and an excipient and being suitable for atomization, wherein the pinene is in a concentration of greater than 80% by weight of the liquid substance; and inhaling the liquid substance.
8.20230030607Novel oxygen pulse therapy method for treating COVID19 and viral, bacterial, fungal or parasitic respiratory and other diseases
US 02.02.2023
Int.Class A61M 16/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
16Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
Appl.No 17382410 Applicant Jose Octavio Hernandez Inventor Jose Octavio Hernandez

A novel oxygen pulse therapy methods of treating subjects suffering from COVID19 and other respiratory and others diseases are provided. Aspects of the methods including administering to the subjects an effective amount of oxygen as pulses through the respiratory tract are included. Also provided are methods of assessing severity of the disease, mild, moderate, severe, or critical, and oxygen doses and frequencies. The method can be applied to viral, bacterial, fungal or parasitic respiratory and others diseases infections such as corona virus (SARS-CoV-2), influenza virus such as influenza A or rotavirus, bacterial pneumonia and meningitis such as Streptococcus pneumonia or parasitic and other diseases such AIDS, Ebola, tuberculosis and malaria.

9.20220008276Pressure Differential-, Ultrasound-, and Magnetic-Based Methods for Treating Viral Infections and other Pathogenic Diseases, Sterilizing Medical Equipment, and Enhancing Fatty Tissue Reduction
US 13.01.2022
Int.Class A61G 10/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
GTRANSPORT, PERSONAL CONVEYANCES, OR ACCOMMODATION SPECIALLY ADAPTED FOR PATIENTS OR DISABLED PERSONS; OPERATING TABLES OR CHAIRS; CHAIRS FOR DENTISTRY; FUNERAL DEVICES
10Treatment rooms for medical purposes
02with artificial climate; with means to maintain a desired pressure, e.g. for germ-free rooms
Appl.No 17369803 Applicant Gabriel Curiel Inventor Gabriel Curiel

The present disclosure is directed to methods of treating subject patients (such as humans, animals, plants) suffering from a pathogenic disease such as COVID-19 in humans, via the administration of pressure changes in the patient sufficient to cause a pressure differential to be created between the inside and outside of the outer membrane or envelope of the pathogen thereby destroying or disabling the pathogen. In one embodiment, a hyperbaric chamber is used to administer pressure increases and/or pressure decreases to create such pressure differential. The hyperbaric chamber could comprise a single user or multi-user unit, a pressurized body suit, or the pressurizable fuselage of an aircraft. In another embodiment, patients are placed in an aircraft, and the cabin pressure, while on the ground, or in flight, is adjusted upwardly or downwardly to create such pressure differential. The pressure differential methods can also include the use of external gases to enter the patient's body and/or lungs to facilitate disruption of the pathogen outer membrane as well as application of variations in temperature and/or humidity. A mobile treatment unit is also disclosed. Also disclosed are methods of using ultrasonic cavitation or MRI (or other sonic or magnetic field forces sufficient to disrupt the functionality of the pathogen), or a combination of ultrasound and MRI on the exterior of a patient in a desired anatomical region of the patient to assist with the destruction or disabling of a pathogen infecting that anatomical region of the patient, e.g., the patient's lungs, said method being employed at ambient pressures or in an increased or decreased pressure environment created within a hyperbaric chamber. The ultrasound and/or MRI methodologies could also be used to treat other pathogenically afflicted areas of the patient's body. Additionally, a pressure-differential method of sterilization of medical equipment is disclosed employing a hyperbaric or other pressure or vacuum chamber. Also disclosed is an enhanced method of nonsurgical fat reduction in humans by employing ultrasonic cavitation within a hyperbaric chamber, including the use of HBOT therapies. Furthermore, the use of these methodologies and systems have application in treatment of patients post-infection and in other areas of medicine and health, such as for example, treating wounds, the effects of aging, inflammation, and the effects of other maladies.

10.WO/2022/011052PRESSURE DIFFERENTIAL-, ULTRASOUND-, AND MAGNETIC-BASED METHODS FOR TREATING VIRAL INFECTIONS AND OTHER PATHOGENIC DISEASES, STERILIZING MEDICAL EQUIPMENT, AND ENHANCING FATTY TISSUE REDUCTION
WO 13.01.2022
Int.Class A61G 10/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
GTRANSPORT, PERSONAL CONVEYANCES, OR ACCOMMODATION SPECIALLY ADAPTED FOR PATIENTS OR DISABLED PERSONS; OPERATING TABLES OR CHAIRS; CHAIRS FOR DENTISTRY; FUNERAL DEVICES
10Treatment rooms for medical purposes
02with artificial climate; with means to maintain a desired pressure, e.g. for germ-free rooms
Appl.No PCT/US2021/040747 Applicant CURIEL, Gabriel Inventor CURIEL, Gabriel
The present disclosure is directed to methods of treating subject patients suffering from a pathogenic disease such as COVID-19 in humans, via the administration of pressure changes in the patient sufficient to cause a pressure differential to be created between the inside and outside of the outer membrane or envelope of the pathogen thereby destroying or disabling the pathogen. A hyperbaric chamber is used to administer pressure increases and/or pressure decreases to create such pressure differential. Also disclosed are methods of using ultrasonic cavitation or MRI, or a combination of ultrasound and MRI on the exterior of a patient in a desired anatomical region of the patient to assist with the destruction or disabling of a pathogen infecting that anatomical region of the patient. An enhanced method of nonsurgical fat reduction in humans by employing ultrasonic cavitation within a hyperbaric chamber, including the use of HBOT therapies, is disclosed.